Replies to post #197298 on Biotech Values

[DewDiligence]

MON—Can't see it happening by way of the GAAP method.

MON’s 5-year guidance (to double EPS from FY2014 to FY2019) has always pertained to "ongoing" (non-GAAP) EPS. It will still be a tough goal to meet.

[DewDiligence]

Do you see anyway MON can increase [non-GAAP EPS by 20% per year for the next 3 years?

Slide #5 (right column) shows the assumptions on which the 20% CAGR for non-GAAP EPS is based:

http://www.monsanto.com/investors/Documents/2015/2015-11-17_BIE/Financial-Translation-Courduroux_2015.11.18.pdf